Role of Osteocytes in Myeloma Bone Disease
骨细胞在骨髓瘤骨病中的作用
基本信息
- 批准号:8736266
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-07-01 至 2018-06-30
- 项目状态:已结题
- 来源:
- 关键词:AdhesionsAffectAffinityAfrican AmericanAgeAnimalsAutomobile DrivingBindingBiological AssayBiologyBone DiseasesBone MatrixBone PainBone ResorptionBone neoplasmsBortezomibBreastCalvariaCell Culture TechniquesCell LineCellsCessation of lifeClinicClinicalClinical TrialsDataDiagnosisEndocrineEnzymesEtiologyExperimental ModelsFibroblast Growth Factor ReceptorsFractureFutureGene TargetingGenesGenetic TranscriptionGrowthGrowth FactorHepatocyte Growth FactorHomingHormone ReceptorHormonesHumanIncidenceIndividualLaboratoriesLifeLuciferasesMalignant Bone NeoplasmMalignant NeoplasmsMalignant neoplasm of lungMediator of activation proteinMessenger RNAMetastatic Neoplasm to the BoneMolecularMorbidity - disease rateMultiple MyelomaMusMyeloma ProteinsNewly DiagnosedOrgan Culture TechniquesOsteoblastsOsteoclastsOsteocytesOsteogenesisOsteolysisOsteolyticPainPathologyPathway interactionsPatientsPharmaceutical PreparationsPlasma CellsPopulationProductionProstateProteasome InhibitorRecombinant Fibroblast Growth FactorRegulationResearch PersonnelRoleSamplingSerumSkeletonSourceTNFSF11 geneTRANCE proteinTestingTimeTreatment CostWorkanimal painbasebonecancer typecell typecostfibroblast growth factor 23heparanaseimprovedinhibitor/antagonistinterestmortalitymouse modeloutcome forecastpatient populationpromoterpublic health relevancereceptorresearch studyresponsesyndecantranscription factortumortumor growth
项目摘要
DESCRIPTION (provided by applicant):
Project Summary Multiple myeloma (MM) grows in and attacks the skeleton, causing pain and bone-related pathologies, such as fracture, as well as contributing to death. Many interactions between the tumor and the bone microenvironment are understood, but none involves pathways unique to bone, and myeloma bone disease (MBD) remains largely incurable. We asked whether factors made only by bone acted specifically on myeloma cells. MM cells, both laboratory cell lines and from patients, expressed the receptor for the hormone fibroblast growth factor (FGF)-23, which is made by osteocytes, abundant cells in bone. In newly diagnosed patients, intact serum FGF23 was 3X higher in MM than in controls. Recombinant FGF23 increased heparanase mRNA 5-18x in 2 MM cell lines at 24hrs. Heparanase is a secreted enzyme that enhances tumor homing and growth in bone and is a marker of poor MM prognosis. It increases bone destruction via the factor RANK ligand and suppresses bone formation, releases growth factors from bone matrix and modifies the MM protein syndecan-1. We propose a new vicious cycle of myeloma bone disease: A) MM cells stimulate osteocytes to secrete FGF23; B) FGF23 increases heparanase expression by MM cells; C) Heparanase alters the bone microenvironment and increases RANK ligand, Dkk1, osteolysis & tumor growth; D) Heparanase increases hepatocyte growth factor (HGF) in bone, which additionally stimulates MM cells; E) FGF23 may enhance MM adhesion to bone. The two Investigators combine extensive individual interests in cancer:bone molecular interactions (JMC) and the biology of clinical myeloma (AS) with a shared interest in the etiology and improved treatment of myeloma bone disease. We propose Four Specific Aims: 1: Determine the cellular pathways by which MM increases FGF23, including testing if known factors made by MM cells regulate FGF23 production, or if it is regulated by heparanase, HGF or the approved MM treatment bortezomib. 2: Determine the role of circulating FGF23 in MM patients, asking if FGF23 & heparanase concentrations are correlated in MM patients and testing if MM cells from patients increase bone release of FGF23. 3: Determine the importance of FGF23-increased heparanase in MBD. 4. Determine molecular mechanisms that control heparanase expression in the bone microenvironment. The project uses a new experimental model of myeloma:bone interactions. In EVOCA (ex vivo organ culture assay), human MM cells are cultured on mouse bone, which supports growth of cell lines and patient samples (which dramatically increase FGF23 in bone). We will make MM cell lines with promoters driving secreted luciferases to analyze changes in gene activity over time in the tumor:bone microenvironment. Experiments with live animal are avoided, lowering costs & increasing efficiency, along with elimination of animal pain & suffering. EVOCA enables new studies in Aim 2 with primary samples to test the importance of the FGF23:heparanase vicious cycle in MBD in individual patients. Inhibitors of FGF23 & heparanase are in clinical trials. Our studies will guide their future application to the treatmentof myeloma bone disease and other cancer bone metastases.
描述(由申请人提供):
多发性骨髓瘤(MM)生长并攻击骨骼,引起疼痛和骨相关的病理,如骨折,以及导致死亡。肿瘤和骨微环境之间的许多相互作用已被了解,但没有一个涉及骨特有的途径,骨髓瘤骨病(MBD)在很大程度上仍然无法治愈。我们想知道是否只有骨骼产生的因子对骨髓瘤细胞有特异性作用。MM细胞,实验室细胞系和患者,表达激素成纤维细胞生长因子(FGF)-23的受体,这是由骨细胞,骨中丰富的细胞。在新诊断的患者中,MM中的完整血清FGF 23比对照高3倍。重组FGF 23在24小时时在2个MM细胞系中使乙酰肝素酶mRNA增加5- 18倍。乙酰肝素酶是一种分泌酶,可促进肿瘤在骨中的归巢和生长,是MM预后不良的标志物。它通过因子RANK配体增加骨破坏并抑制骨形成,从骨基质释放生长因子并修饰MM蛋白多配体聚糖-1。我们提出了一种新的骨髓瘤骨病恶性循环:A)MM细胞刺激骨细胞分泌FGF 23; B)FGF 23增加MM细胞的乙酰肝素酶表达; C)乙酰肝素酶改变骨微环境并增加RANK配体、Dkk 1、骨质溶解和肿瘤生长; D)乙酰肝素酶增加骨中的肝细胞生长因子(HGF),这额外刺激MM细胞; E)FGF 23可以增强MM对骨的粘附。两位研究者联合收割机结合了对癌症的广泛个人兴趣:骨分子相互作用(JMC)和临床骨髓瘤(AS)的生物学,以及对骨髓瘤骨病的病因学和改进治疗的共同兴趣。我们提出四个具体目标:一曰:确定MM增加FGF 23的细胞途径,包括检测MM细胞产生的已知因子是否调节FGF 23的产生,或者是否受乙酰肝素酶、HGF或批准的MM治疗药物硼替佐米的调节。第二章:确定MM患者中循环FGF 23的作用,询问MM患者中FGF 23和乙酰肝素酶浓度是否相关,并测试来自患者的MM细胞是否增加FGF 23的骨释放。3:确定MBD中FGF 23增加的乙酰肝素酶的重要性。4.确定控制骨微环境中乙酰肝素酶表达的分子机制。该项目使用了一种新的骨髓瘤实验模型:骨相互作用。在EVOCA(离体器官培养试验)中,人MM细胞在小鼠骨上培养,这支持细胞系和患者样本的生长(这显著增加了骨中的FGF 23)。我们将使MM细胞系具有驱动分泌型端粒酶的启动子,以分析肿瘤:骨微环境中基因活性随时间的变化。避免了用活体动物进行实验,降低了成本,提高了效率,沿着消除了动物的痛苦。EVOCA使Aim 2的新研究能够使用原始样本来测试个体患者中MBD中FGF 23:乙酰肝素酶恶性循环的重要性。FGF 23和乙酰肝素酶的抑制剂正在临床试验中。我们的研究将指导其在骨髓瘤骨病和其他癌症骨转移治疗中的未来应用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOHN M CHIRGWIN其他文献
JOHN M CHIRGWIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOHN M CHIRGWIN', 18)}}的其他基金
Manipulating the N-end Rule Protein Degradation Pathway to Build Bone and Decrease Tumor Growth in Multiple Myeloma Bone Disease
操纵 N 端规则蛋白降解途径来构建骨并减少多发性骨髓瘤骨病中的肿瘤生长
- 批准号:
10582710 - 财政年份:2020
- 资助金额:
-- - 项目类别:
A Novel Agent to Suppress Tumor Growth in Bone, Prevent Cachectic Muscle Loss and Preserve Skeletal Integrity
一种抑制骨肿瘤生长、防止恶病质肌肉损失并保持骨骼完整性的新型药物
- 批准号:
10158431 - 财政年份:2019
- 资助金额:
-- - 项目类别:
A Novel Agent to Suppress Tumor Growth in Bone, Prevent Cachectic Muscle Loss and Preserve Skeletal Integrity
一种抑制骨肿瘤生长、防止恶病质肌肉损失并保持骨骼完整性的新型药物
- 批准号:
10454796 - 财政年份:2019
- 资助金额:
-- - 项目类别:
A Novel Agent to Suppress Tumor Growth in Bone, Prevent Cachectic Muscle Loss and Preserve Skeletal Integrity
一种抑制骨肿瘤生长、防止恶病质肌肉损失并保持骨骼完整性的新型药物
- 批准号:
9912632 - 财政年份:2019
- 资助金额:
-- - 项目类别:
相似海外基金
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
- 批准号:
2301846 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
- 批准号:
23K16076 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Early-Career Scientists